We are live on ! Find out more
GT

Glenmede Trust Portfolio holdings

AUM $20.4B
This Fund
S&P 500
This Quarter Est. Return
+8.99%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$21.9B
AUM Growth
+$21.9B
Cap. Flow
-$417M
Cap. Flow %
-1.9%
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$89.3M
2
KEYS icon
Keysight
KEYS
+$86M
3
NKE icon
Nike
NKE
+$78.3M
4
APH icon
Amphenol
APH
+$76.5M
5
CMCSA icon
Comcast
CMCSA
+$72.3M

Top Sells

Rank Stock Value
1
CE icon
Celanese
CE
+$108M
2
MNST icon
Monster Beverage
MNST
+$97.8M
3
SBUX icon
Starbucks
SBUX
+$79.7M
4
TXN icon
Texas Instruments
TXN
+$67.3M
5
CNC icon
Centene
CNC
+$64.3M

Sector Composition

Rank Sector Weight
1 Technology 18.83%
2 Financials 13.42%
3 Healthcare 13.25%
4 Industrials 9.77%
5 Consumer Discretionary 7.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CHCO icon
1901
City Holding Co
CHCO
$2.04B
$12K ﹤0.01%
147
CMP icon
1902
Compass Minerals
CMP
$1.25B
$12K ﹤0.01%
212
-11
-5% -$624
CMTL icon
1903
Comtech Telecommunications
CMTL
$51.5M
$12K ﹤0.01%
365
+93
+34% +$3.2K
COKE icon
1904
Coca-Cola Consolidated
COKE
$13B
$12K ﹤0.01%
440
+120
+38% +$3.36K
CORT icon
1905
Corcept Therapeutics
CORT
$10.1B
$12K ﹤0.01%
1,069
+350
+49% +$4.87K
CPRT icon
1906
Copart
CPRT
$28.4B
$12K ﹤0.01%
528
+512
+3,200% +$10.9K
CVCO icon
1907
Cavco Industries
CVCO
$4.54B
$12K ﹤0.01%
65
+21
+48% +$4.12K
DXCM icon
1908
DexCom
DXCM
$28.9B
$12K ﹤0.01%
228
-492
-68% -$23.3K
FLEX icon
1909
Flex
FLEX
$41.5B
$12K ﹤0.01%
1,314
GTY
1910
Getty Realty Corp
GTY
$2.17B
$12K ﹤0.01%
390
+99
+34% +$3.26K
HEWJ icon
1911
iShares Currency Hedged MSCI Japan ETF
HEWJ
$718M
$12K ﹤0.01%
375
MCHB
1912
Mechanics Bancorp
MCHB
$3.51B
$12K ﹤0.01%
367
+105
+40% +$3.25K
LNN icon
1913
Lindsay Corp
LNN
$1.17B
$12K ﹤0.01%
127
+37
+41% +$3.38K
LRN icon
1914
Stride
LRN
$4.08B
$12K ﹤0.01%
600
MTRN icon
1915
Materion
MTRN
$4.36B
$12K ﹤0.01%
202
+59
+41% +$3.49K
PBI icon
1916
Pitney Bowes
PBI
$2.41B
$12K ﹤0.01%
3,361
+696
+26% +$3.19K
PDBC icon
1917
Invesco Actively Managed Exch-Traded Commodity Fd Tr Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF
PDBC
$6.2B
$12K ﹤0.01%
738
R icon
1918
Ryder
R
$9.98B
$12K ﹤0.01%
229
+171
+295% +$8.9K
RRC icon
1919
Range Resources
RRC
$8.94B
$12K ﹤0.01%
2,633
-293,951
-99% -$1.19M
RWT
1920
Redwood Trust
RWT
$587M
$12K ﹤0.01%
777
+272
+54% +$4.47K
SSL icon
1921
Sasol
SSL
$7.03B
$12K ﹤0.01%
565
+110
+24% +$2.1K
TNK icon
1922
Teekay Tankers
TNK
$2.66B
$12K ﹤0.01%
527
-126
-19% -$2.29K
UGP icon
1923
Ultrapar
UGP
$6.74B
$12K ﹤0.01%
2,034
+836
+70% +$4.25K
UVV icon
1924
Universal Corp
UVV
$1.36B
$12K ﹤0.01%
215
+74
+52% +$3.99K
VNO.PRL icon
1925
Vornado Realty Trust 5.40% Series L Preferred Shares
VNO.PRL
$211M
$12K ﹤0.01%
500

Similar funds

Glenmede Trust's Q4 2019 Portfolio in Review

As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

  • Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
  • Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
  • Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
  • Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
  • Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
  • Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
  • Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.